|ZFIN ID: ZDB-PUB-051128-10|
Identification of Zebrafish ARNT1 Homologs: 2,3,7,8-Tetrachlorodibenzo-p-dioxin Toxicity in the Developing Zebrafish Requires ARNT1
Prasch, A.L., Tanguay, R.L., Mehta, V., Heideman, W., and Peterson, R.E.
|Source:||Molecular pharmacology 69(3): 776-787 (Journal)|
|Registered Authors:||Heideman, Warren, Mehta, Vatsal, Peterson, Richard E., Prasch, Amy, Tanguay, Robyn L.|
|Keywords:||Regulation of gene expression, Ah receptor, Toxicant-induced gene express|
|PubMed:||16306231 Full text @ Mol. Pharmacol.|
Prasch, A.L., Tanguay, R.L., Mehta, V., Heideman, W., and Peterson, R.E. (2006) Identification of Zebrafish ARNT1 Homologs: 2,3,7,8-Tetrachlorodibenzo-p-dioxin Toxicity in the Developing Zebrafish Requires ARNT1. Molecular pharmacology. 69(3):776-787.
ABSTRACTIn order to use the zebrafish as a model to study 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) developmental toxicity, it is essential to know which proteins are involved in mediating toxicity. Previous work has identified zfAHR2 as the receptor which binds TCDD mediating downstream responses. Although zfARNT2b can form a functional heterodimer with zfAHR2 in vitro, zfarnt2 null mutants show no protection against endpoints of TCDD developmental toxicity demonstrating that zfARNT2b cannot be the physiological dimerization partner for zfAHR2 mediating responses to TCDD in zebrafish embryos. The purpose of the current study was to identify an alternate dimerization partner(s) for zfAHR2 that may function to mediate TCDD developmental toxicity. By searching zebrafish genomic sequence and employing the PCR-based RACE technique, three forms of cDNA that appear to be alternate mRNA splice variants of a zebrafish homolog of ARNT1 were detected. Analysis of the zfARNT1 proteins in vitro demonstrates that the two longest forms of zfARNT1, zfARNT1b and zfARNT1c, can form functional heterodimers with zfAHR2. However, the shortest form, zfARNT1a, appears to be nonfunctional with zfAHR2 in vitro. In order to determine if a zfARNT1 protein functions with zfAHR2 in vivo, a morpholino targeted against the 5' end of zfARNT1 (zfarnt1-MO) was used. Injection of the zfarnt1-MO prior to TCDD treatment significantly decreases the induction of zfCYP1A mRNA and protein. In addition, zfarnt1 morphants show complete protection against TCDD-induced pericardial edema and show partial protection against reduced blood flow and craniofacial malformations caused by TCDD demonstrating the role of zfARNT1 proteins in mediating these responses.